January - March 2013

March 27, 2013		Takeda Submits New Drug Applications in Japan for Cell Culture-BasedPandemic Influenza Vaccines with its Hikari Plant
March 27, 2013		Takeda Submits a New Drug Application for the Fixed-Dose Combination of Takepron and Low-Dose Aspirin in Japan
March 25, 2013		Takeda Receives a Decision by the President of National Tax TribunalRelating to the Correction Notice on Transfer Pricing
March 22, 2013		Takeda Submits New Drug Application for Brentuximab Vedotin in Japan
March 21, 2013		Takeda Announces the Appointment of New Senior Leadership and Organizational Change
March 21, 2013		JPMA's Sanction to Takeda for a Violation of the Pharmaceutical Affairs Act Related to the Voluntary Recall of ALINAMIN®-F5 Injection in Japan
March 19, 2013		NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and Recombinant Human Parathyroid Hormone 1-84
March 8, 2013		Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union
February 28, 2013		Takeda and Resolve Therapeutics Enter Autoimmune Partnership
February 28, 2013		BENET® Tablets 75 mg, a Once-Monthly Formulation of an Antiosteoporotic Agent Now Available in Japan
February 27, 2013		Takeda Announces the Establishment of New Organization, Change of Organization Name, and Appointment of New Leadership
February 24, 2013		Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of OMONTYS® (peginesatide) Injection
February 21, 2013		Helicobacter pylori Gastritis Approved as Additional Indication in Japan for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitor
February 13, 2013		Administrative Sanction Related to Voluntary Recall of ALINAMIN®-F5 Injection in Japan
January 28, 2013		Data From Post-Marketing Survey of Vectibix® for the Treatment of Colorectal Cancer Reported at American Society of Clinical Oncology, 2013 Gastrointestinal Cancers Symposium
January 26, 2013		Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
January 22, 2013		Takeda Establishes New Trading Company and Reinforces Business Structure in China
January 10, 2013		Lotriga® 2g Now Available for a Treatment of Hyperlipidemia in Japan

• 
• • 1
•